Gadoquatrane - Bayer
Alternative Names: BAY-1747846Latest Information Update: 20 Jun 2025
At a glance
- Originator Bayer
- Class Contrast media; Gadolinium-containing contrast agents; Heavy metals; Macrocyclic compounds
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration CNS disorders
- Phase III Peripheral nervous system diseases
Most Recent Events
- 18 Jun 2025 Preregistration for CNS disorders (Diagnosis, In adults, In adolescents, In children, In infants, In neonates) in USA (IV)
- 02 Jun 2025 Preregistration for CNS disorders (Diagnosis, In adolescents, In children, In infants, In neonates, In adults) in Japan (IV)
- 26 Feb 2025 Positive efficacy and adverse events data from the phase III QUANTI CNS trial in CNS disorders released by Bayer